Mimedx (MDXG) Common Equity (2010 - 2026)

Mimedx (MDXG) has 17 years of Common Equity data on file, last reported at $242.9 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 19.81% year-over-year to $242.9 million; the trailing twelve-month figure through Mar 2026 stood at $242.9 million (up 19.81% YoY), and the FY2025 full-year result was $256.5 million, up 32.85% from the prior year.
• Common Equity slipped to $242.9 million in Q1 2026, from $256.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $256.5 million in Q4 2025 to a low of -$19.5 million in Q3 2022.
• A 5-year average of $112.4 million and a median of $155.7 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 22036.59% in 2022 and surged 13509.62% in 2024, its largest moves.
• Tracing MDXG's Common Equity over 5 years: stood at -$18.0 million in 2022, then surged by 893.4% to $142.7 million in 2023, then jumped by 35.31% to $193.1 million in 2024, then surged by 32.85% to $256.5 million in 2025, then fell by 5.31% to $242.9 million in 2026.
• Business Quant data shows MDXG's Common Equity at $242.9 million in Q1 2026, $256.5 million in Q4 2025, and $238.9 million in Q3 2025.